• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
187676 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  $ g+ X5 n: m" |) e& [* \
$ T' J2 W) t( Y

, I- m$ b( U' {% M3 u5 NSub-category:
% k7 M5 n: c: N* i" RMolecular Targets 7 h: n) Q; I/ l( P
) o/ |1 W0 V: [2 u: j: Y$ V
: _4 @: e7 {- \) w1 N7 ?9 [1 n
Category:9 _  R) w6 H# g: ?
Tumor Biology * K! V* {  ^5 {9 q' ]7 P0 R

( `0 I4 V- Z8 E' `- c: [' Q1 J# u. w4 L: a) e
Meeting:
7 R3 s6 n. C/ [9 R2011 ASCO Annual Meeting % W8 V; A$ j+ n
' Y9 v% e& ?1 R; e: V+ n
- v9 [6 L4 }% D" ]
Session Type and Session Title:
% r2 @( X, c9 P6 Y* ^Poster Discussion Session, Tumor Biology ( t3 }, Q% K( y1 U9 a
$ B8 Z9 x* {, W% v: L. h( ?

( N. i' f8 b/ }: g7 I% A9 f$ z# }# o4 `Abstract No:
0 G4 E" y1 s  Z7 Z4 t; c10517
% ?) `& [" o7 Y" {' M! m) ~& O/ g% I4 ]: v

1 }3 i% M, ?' w5 b+ l" E+ Q' yCitation:7 C; r2 T, ^& v+ p
J Clin Oncol 29: 2011 (suppl; abstr 10517)
+ c6 l) f5 s5 w: s( i! \( e
5 j% L  U6 F( M/ T' J$ Z7 U
2 k1 }2 p, f+ _' ^0 h1 Y) }! i% h. T: \7 sAuthor(s):
# }( d" M/ x) s, IJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
9 {/ A% K5 ^3 Q  j. l7 q9 S- h# A9 {" U

6 @/ D2 B- Q! ]7 d' j7 o5 n2 A
" z. i. i! j% F3 P. T9 p9 j( t2 U3 GAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.5 o( M9 c2 L! N8 B2 r

- U' X% s+ l; B# `9 _Abstract Disclosures
5 X" K  ^) o$ O+ o! g% U; \& q+ z( V; e% o; u* O
Abstract:
4 h8 a3 e# ~% X& \; `
* K( a3 b/ m! }$ E- W  C, b; D9 f; v0 y4 I& \' H' Z
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.# h. w; g" p: j4 m5 D
2 X8 n. @# e! W4 P3 U

) j8 }6 p! }$ y: k4 Z! }
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
) }" d+ `; G, _; P) t没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

9 ?, o' Q/ }% ?( b4 I化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
6 u3 _& D6 N/ b( y- H/ ?6 |易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。/ N5 H" w' k- u8 B1 W
ALK一个指标医院要900多 ...

: ^& p; M' A( W0 C- y平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
7 s3 j3 w+ y% W  B4 E: V; y
9 ?7 {1 V7 s( B. D! A$ U现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表